https://www.onclive.com/view/dr-geyer-on-the-fda-approval-of-t-dxd-followed-by-thp-for-her2-breast-cancer2026-06-30T22:35:00Z2026-06-30T22:35:00Z https://www.onclive.com/view/dr-geyer-on-the-fda-approval-of-post-neoadjuvant-t-dxd-for-her2-breast-cancer2026-06-30T22:25:00Z2026-06-30T22:25:00Z https://www.onclive.com/view/glp-1-receptor-agonists-endocrine-therapy-and-metabolic-health-comprise-holistic-breast-cancer-care2026-06-30T21:58:31.419Z2026-06-30T21:58:31.419Z https://www.onclive.com/view/fda-approves-orca-t-for-matched-donor-hsct-in-hematologic-malignancies2026-06-30T21:56:40.596Z2026-06-30T21:56:40.596Z https://www.onclive.com/view/dr-vachhani-on-phase-2-efficacy-safety-data-for-sapablursen-in-polycythemia-vera2026-06-30T21:40:18.928Z2026-06-30T21:40:18.928Z https://www.onclive.com/view/dissecting-independence-data-and-the-role-of-luspatercept-in-myelofibrosis-associated-anemia-with-claire-harrison-md2026-06-30T21:11:56.374Z2026-06-30T21:11:56.374Z https://www.onclive.com/view/frontline-treatment-selection-in-egfr-mutated-non-small-cell-lung-cancer-monotherapy-versus-combination-strategies2026-06-30T21:00:00Z2026-06-30T21:00:00Z https://www.onclive.com/view/cns-surveillance-standards-and-practice-gaps-in-egfr-mutated-nsclc2026-06-30T20:07:19.160Z2026-06-30T20:07:19.160Z https://www.onclive.com/view/dr-ailawadhi-on-the-investigation-of-cemsidomide-in-multiple-myeloma2026-06-30T20:06:14.810Z2026-06-30T20:06:14.810Z https://www.onclive.com/view/first-line-cns-efficacy-in-egfr-mutated-nsclc-flaura2-and-mariposa-data2026-06-30T20:06:11.946Z2026-06-30T20:06:11.946Z https://www.onclive.com/view/as-adc-options-expand-sequencing-and-toxicity-management-become-the-next-challenges-in-gynecologic-oncology2026-06-30T19:49:16.172Z2026-06-30T19:49:16.172Z https://www.onclive.com/view/serena-6-splits-the-breast-cancer-field-on-switching-therapy-before-radiographic-progression-with-sara-nunnery-md-msci-and-megan-kruse-md2026-06-30T19:45:00Z2026-06-30T19:45:00Z https://www.onclive.com/view/medical-crossfire-turning-therapeutic-innovation-into-practice-personalizing-care-in-multiple-myeloma2026-06-30T19:33:31.821Z2026-06-30T19:33:31.821Z https://www.onclive.com/view/intensive-chemotherapy-in-combination-with-quizartinib-versus-midostaurin-for-flt3-itd-mutated-acute-myeloid-leukemia-a-multicenter-cohort-study2026-06-30T19:22:43.184Z2026-06-30T19:22:43.184Z https://www.onclive.com/view/zanubrutinib-vs-ibrutinib-in-tb-cll-implications-for-interpreting-fixed-duration-treatment-outcomes-from-cll172026-06-30T18:33:15.106Z2026-06-30T18:33:15.106Z https://www.onclive.com/view/foundations-of-metastatic-tnbc-biology-prognosis-and-the-treatment-paradigm2026-06-30T18:15:00.000Z2026-06-30T18:15:00Z https://www.onclive.com/view/mangrove-trial-shows-improved-efficacy-with-zanubrutinib-plus-rituximab-vs-chemo-in-mcl2026-06-30T17:45:00Z2026-06-30T17:45:00Z https://www.onclive.com/view/treatment-intensification-in-vulnerable-populations-arpi-use-in-elderly-frail-and-high-comorbidity-patients-with-mcspc-with-martin-schoen-md-and-andrew-w-hahn-md2026-06-30T17:00:00Z2026-06-30T17:00:00Z https://www.onclive.com/view/10-experts-predict-future-ctcl-treatment2026-06-30T16:42:57.722Z2026-06-30T16:42:57.722Z https://www.onclive.com/view/mayo-clinic-researchers-uncover-critical-link-in-the-immune-response-to-cancer2026-06-30T16:12:10.304Z2026-06-30T16:12:10.304Z https://www.onclive.com/view/experts-outline-the-evolving-role-of-ctdna-based-mrd-testing-across-solid-tumors2026-06-30T15:28:21.783Z2026-06-30T15:28:21.783Z https://www.onclive.com/view/multidisciplinary-communication-and-fda-approval-pathway-fundamentals2026-06-30T15:05:00.000Z2026-06-30T15:05:00Z https://www.onclive.com/view/evolution-of-radioligand-therapy-in-nets2026-06-30T15:00:00.000Z2026-06-30T15:00:00Z https://www.onclive.com/view/annamycin-plus-cytarabine-generates-higher-complete-remission-rates-vs-control-in-r-r-aml2026-06-30T14:38:00Z2026-06-30T14:38:00Z https://www.onclive.com/view/epcoritamab-plus-lenalidomide-improves-pfs-vs-r-gemox-in-r-r-dlbcl2026-06-30T14:16:34.155Z2026-06-30T14:16:34.155Z https://www.onclive.com/view/frontmind-trial-results2026-06-30T14:16:31.309Z2026-06-30T14:16:31.309Z https://www.onclive.com/view/frontline-landscape-overview-and-biomarker-testing-in-dlbcl2026-06-30T14:13:29.858Z2026-06-30T14:13:29.858Z https://www.onclive.com/view/sequencing-and-emerging-targets-revamp-the-platinum-resistant-ovarian-cancer-treatment-paradigm-with-david-o-malley-md2026-06-30T14:00:00Z2026-06-30T14:00:00Z https://www.onclive.com/view/early-stage-breast-cancer-evolution-of-genomic-testing2026-06-30T14:00:00Z2026-06-30T14:00:00Z https://www.onclive.com/view/dr-stein-on-the-background-of-the-phase-3-optima-trial-in-er-her2-early-breast-cancer2026-06-30T13:00:00Z2026-06-30T13:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-managing-pi3k-directed-triplet-therapy-and-treatment-related-toxicities2026-06-30T12:15:00Z2026-06-30T12:15:00Z https://www.onclive.com/view/why-pi3k-is-a-target-and-what-makes-duvelisib-different2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.onclive.com/view/tarlatamab-mechanism-and-dellphi-305-trial-design2026-06-23T12:05:00.000Z2026-06-30T12:05:00Z https://www.onclive.com/view/optimizing-timing-of-adjuvant-cdk4-6-inhibitor-initiation-in-clinical-practice2026-06-30T12:05:00Z2026-06-30T12:05:00Z https://www.onclive.com/view/further-integrating-biosimilars-into-oncology-the-role-of-wyost-denosumab-bbdz-in-preventing-cancer-related-skeletal-events-with-bone-metastases-from-solid-tumors2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/defining-high-risk-hr-her2-early-breast-cancer-for-adjuvant-cdk4-6-therapy2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/tremelimumab-durvalumab-chemotherapy-vs-pembrolizumab-chemotherapy-in-1l-non-squamous-metastatic-nsclc-with-stk11-keap1-and-or-kras-mutations-interim-analysis-of-the-phase-2b-triton-study2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/dr-fakih-on-the-strategic-timing-and-concordance-of-biopsies-in-crc2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-triplet-therapy-implementation-and-management-after-prior-cdk4-6-inhibitor-exposure2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/the-us-landscape-and-the-regulatory-bottleneck-in-ptcl2026-06-30T12:00:00Z2026-06-30T12:00:00Z https://www.onclive.com/view/administration-logistics-and-g-csf-prophylaxis-in-es-sclc2026-06-23T12:05:00.000Z2026-06-30T12:00:00Z https://www.onclive.com/view/fda-issues-crl-to-pet-diagnostic-imaging-kit-for-gallium-68-edotreotide-in-sstr-nets2026-06-29T22:20:00Z2026-06-29T22:20:00Z https://www.onclive.com/view/elisrasib-yields-durable-responses-in-pretreated-kras-g12c-mutant-nsclc2026-06-29T21:45:00Z2026-06-29T21:45:00Z https://www.onclive.com/view/unlocking-the-power-of-ctdna-for-residual-disease-resistance-monitoring-and-real-time-treatment-decisions-in-gi-cancers-with-christopher-lieu-md2026-06-29T20:03:56.570Z2026-06-29T20:03:56.570Z https://www.onclive.com/view/revumenib-intensive-chemotherapy-for-newly-diagnosed-acute-myeloid-leukemia-harboring-genetic-alterations-in-kmt2a-npm1-or-nup98-updated-phase-1-results-from-sndx-5613-07082026-06-29T20:00:00Z2026-06-29T20:00:00Z https://www.onclive.com/view/romiplostim-n01-promotes-platelet-recovery-after-unrelated-cord-blood-transplant-in-hematologic-malignancies2026-06-29T19:56:13.651Z2026-06-29T19:56:13.651Z https://www.onclive.com/view/dr-stein-on-the-key-clinical-implications-of-data-from-the-optima-trial-in-er-her2-early-breast-cancer2026-06-29T19:00:00Z2026-06-29T19:00:00Z https://www.onclive.com/view/dr-randall-on-the-use-of-tumor-informed-ctdna-deep-sequencing-for-osteosarcoma-risk-stratification2026-06-29T18:23:15.188Z2026-06-29T18:23:15.188Z https://www.onclive.com/view/dr-thomas-on-the-efficacy-of-first-line-ipatasertib-plus-pembrolizumab-in-hnscc2026-06-29T18:00:00Z2026-06-29T18:00:00Z https://www.onclive.com/view/multidisciplinary-tumor-board-integration-of-ctdna-results2026-06-29T17:22:00Z2026-06-29T17:22:00Z https://www.onclive.com/view/treatment-on-molecular-recurrence-and-access-barriers2026-06-29T17:20:49.355Z2026-06-29T17:20:49.355Z https://www.onclive.com/view/dr-orloff-on-key-findings-from-the-phase-2-3-optimum-02-trial-in-uveal-melanoma2026-06-29T17:00:00Z2026-06-29T17:00:00Z https://www.onclive.com/view/t-dxd-wins-eu-approval-for-previously-treated-her2-metastatic-solid-tumors2026-06-29T16:47:35.263Z2026-06-29T16:47:35.263Z https://www.onclive.com/view/dana-farber-uses-ai-to-design-proteins-that-could-make-cancer-drugs-safer-and-more-precise2026-06-29T16:00:00Z2026-06-29T16:00:00Z https://www.onclive.com/view/pembrolizumab-biosimilar-meets-primary-phase-1-and-phase-3-end-points-in-nsclc2026-06-29T14:13:57.711Z2026-06-29T14:13:57.711Z https://www.onclive.com/view/updated-overall-survival-and-long-term-transfusion-independence-from-the-phase-3-commands-trial-in-erythropoiesis-stimulating-agent-naive-patients-with-lower-risk-myelodysplastic-syndromes2026-06-29T13:51:08.041Z2026-06-29T13:51:08.041Z https://www.onclive.com/view/dr-fakih-on-practical-applications-of-liquid-and-tissue-biopsies-in-crc2026-06-29T13:40:01.733Z2026-06-29T13:40:01.733Z https://www.onclive.com/view/fda-approval-insights-decitabine-cedazuridine-plus-venetoclax-for-aml-with-courtney-d-dinardo-md-msce2026-06-29T13:00:00Z2026-06-29T13:00:00Z https://www.onclive.com/view/indirect-comparison-of-the-efficacy-of-zanubrutinib-vs-ibrutinib-and-acalabrutinib-in-treatment-naive-chronic-lymphocytic-leukemia-6-year-follow-up2026-06-29T12:32:38.243Z2026-06-29T12:32:38.243Z https://www.onclive.com/view/her2-positive-early-breast-cancer-applying-destiny-breast11-in-clinical-practice2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.onclive.com/view/cll14-long-term-follow-up-and-ighv-guided-treatment-selection2026-06-29T12:05:00Z2026-06-29T12:05:00Z https://www.onclive.com/view/real-world-outcomes-of-zanubrutinib-vs-acalabrutinib-in-first-line-cll2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/t-dxd-plus-pertuzumab-sets-new-treatment-and-research-standards-in-her2-breast-cancer2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/first-line-cll-treatment-framework2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-interpreting-destiny-breast11-trial-design2026-06-29T12:00:00Z2026-06-29T12:00:00Z https://www.onclive.com/view/dr-specht-on-the-significance-of-data-for-mogamulizumab-vs-soc-in-denmark-for-patients-with-mf-ss2026-06-28T22:08:18.871Z2026-06-28T22:08:18.871Z https://www.onclive.com/view/dr-stuver-on-how-to-approach-pcptcl-nos-treatment-decision-making2026-06-28T19:00:00Z2026-06-28T19:00:00Z https://www.onclive.com/view/dr-prince-on-the-design-of-the-comparison-of-mavoric-and-real-world-vorinostat2026-06-28T16:59:24.274Z2026-06-28T16:59:24.274Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-212026-06-28T14:41:01.092Z2026-06-28T14:41:01.092Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-6-212026-06-28T13:42:04.972Z2026-06-28T13:42:04.972Z https://www.onclive.com/view/generic-enzalutamide-tablets-granted-tentative-fda-approval-for-prostate-cancer2026-06-28T12:35:34.415Z2026-06-28T12:35:34.415Z https://www.onclive.com/view/dr-mehta-shah-on-novel-ctcl-target-research2026-06-27T17:42:04.209Z2026-06-27T17:42:04.209Z https://www.onclive.com/view/st-001-nanofenretinide-shows-antitumor-activity-in-previously-treated-cutaneous-t-cell-lymphoma2026-06-27T17:30:58.904Z2026-06-27T17:30:58.904Z https://www.onclive.com/view/dr-mehta-shah-on-the-future-of-ctcl-novel-drug-development2026-06-27T17:25:59.432Z2026-06-27T17:25:59.432Z https://www.onclive.com/view/pegylated-interferon-alfa-2a-is-safe-and-tolerable-in-real-world-ctcl-study2026-06-27T17:13:00.228Z2026-06-27T17:13:00.228Z https://www.onclive.com/view/dr-scarisbrick-on-refining-mf-sezary-treatment-with-prosper-findings2026-06-27T17:05:15.155Z2026-06-27T17:05:15.155Z https://www.onclive.com/view/dr-scarisbrick-on-mogamulizumab-outcomes-in-prosper2026-06-27T16:53:36.863Z2026-06-27T16:53:36.863Z https://www.onclive.com/view/fda-approves-prefilled-pen-for-ropeginterferon-alfa-2b-njft-in-polycythemia-vera2026-06-27T16:33:24.748Z2026-06-27T16:33:24.748Z https://www.onclive.com/view/immune-and-single-cell-profiling-reveals-drivers-of-mogamulizumab-resistance-in-mf-and-ss2026-06-27T16:30:33.012Z2026-06-27T16:30:33.012Z https://www.onclive.com/view/duvelisib-nivolumab-immune-toxicities-limit-dosing-pretreated-ctcl2026-06-27T14:00:00Z2026-06-27T14:00:00Z https://www.onclive.com/view/mogamulizumab-improves-patient-reported-symptoms-and-hrqol-in-mycosis-fungoides-s-zary-syndrome2026-06-27T13:00:00Z2026-06-27T13:00:00Z https://www.onclive.com/view/chmp-recommends-pirtobrutinib-for-eu-approval-in-cll-across-all-lines-of-therapy2026-06-27T01:32:30.233Z2026-06-27T01:32:30.233Z https://www.onclive.com/view/extended-teclistamab-daratumumab-indication-approaches-eu-approval-in-r-r-multiple-myeloma2026-06-27T00:58:10.779Z2026-06-27T00:58:10.779Z https://www.onclive.com/view/dibotatug-is-safe-and-shows-activity-in-r-r-cytotoxic-t-nk-cell-lymphomas2026-06-27T00:33:08.579Z2026-06-27T00:33:08.579Z https://www.onclive.com/view/dr-querfeld-on-achieving-patient-satisfaction-with-mogamulizumab2026-06-26T23:51:12.065Z2026-06-26T23:51:12.065Z https://www.onclive.com/view/dr-querfeld-on-sequencing-strategies-for-mogamulizumab2026-06-26T23:37:35.145Z2026-06-26T23:37:35.145Z https://www.onclive.com/view/dr-nicolay-on-biomarkers-and-mechanisms-to-support-mogamulizumab2026-06-26T23:15:23.894Z2026-06-26T23:15:23.894Z https://www.onclive.com/view/dr-nicolay-on-the-biologic-response-to-mogamulizumab2026-06-26T23:13:56.770Z2026-06-26T23:13:56.770Z https://www.onclive.com/view/wccl-debate-how-to-classify-sptcl2026-06-26T22:51:56.450Z2026-06-26T22:51:56.450Z https://www.onclive.com/view/bi-1808-shows-efficacy-as-monotherapy-and-in-combination-with-pembrolizumab-in-t-cell-lymphomas2026-06-26T21:25:00Z2026-06-26T21:25:00Z https://www.onclive.com/view/real-world-mogamulizumab-elicits-durable-responses-in-pretreated-mycosis-fungoides-and-s-zary-syndrome2026-06-26T18:50:00Z2026-06-26T18:50:00Z https://www.onclive.com/view/dr-stein-on-test-directed-chemotherapy-in-er-her2-early-breast-cancer2026-06-26T16:42:19.067Z2026-06-26T16:42:19.067Z https://www.onclive.com/view/dato-dxd-earns-chmp-positive-opinion-for-first-line-metastatic-tnbc2026-06-26T16:05:51.992Z2026-06-26T16:05:51.992Z https://www.onclive.com/view/surgical-manual-from-roswell-park-created-to-advance-bladder-cancer-surgery-worldwide2026-06-26T16:00:00Z2026-06-26T16:00:00Z https://www.onclive.com/view/fda-accepts-third-rp1-bla-resubmission-with-nivolumab-in-advanced-melanoma2026-06-26T15:28:54.373Z2026-06-26T15:28:54.373Z https://www.onclive.com/view/live-tumor-board-translating-biomarker-insights-and-therapeutic-advances-into-endometrial-cancer-practice2026-06-26T14:13:18.431Z2026-06-26T14:13:18.431Z https://www.onclive.com/view/dr-morgans-on-the-clinical-significance-of-data-from-the-aracog-trial-in-prostate-cancer2026-06-26T13:00:00Z2026-06-26T13:00:00Z https://www.onclive.com/view/selecting-and-sequencing-first-line-therapy-in-alk-positive-nsclc2026-06-26T12:05:00Z2026-06-26T12:05:00Z https://www.onclive.com/view/top-study-design-and-results2026-06-26T12:03:00Z2026-06-26T12:03:00Z https://www.onclive.com/view/introduction-and-tp53-background-in-egfr-mutant-nsclc2026-06-26T12:01:00Z2026-06-26T12:01:00Z